PharmaEssentia (6446) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was NT$5,121 million, up 57% year-over-year, with net income of NT$2,150 million, a 70% increase from Q1 2025.

• Gross margin improved to 88%, and EPS rose to NT$5.79 from NT$3.42 year-over-year.

• Cash and cash equivalents at quarter-end were NT$24,175 million, up from NT$22,034 million a year ago.

Financial highlights

• Operating income for Q1 2026 was NT$2,087 million, up from NT$1,105 million year-over-year.

• Total assets increased to NT$40,090 million, up 21% from NT$33,024 million year-over-year.

• Equity attributable to owners reached NT$34,454 million, representing 86% of total assets.

• Operating cash flow for Q1 2026 was NT$1,734 million, up from NT$1,061 million year-over-year.

Outlook and guidance

• The company is expanding manufacturing capacity and investing in new subsidiaries in Puerto Rico and Canada to support global growth.

• Ongoing clinical trials and product launches are expected to drive future revenue.